CD47 and anemia: As a result of the ubiquitous expression and unique properties of CD47, more attention is now principally being focused on haematotoxicity, including anaemia and thrombocytopenia, caused by the administration of anti‐CD47 blocking antibodies in clinical oncology studies [17, 18, 19].